Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
By P. Richardson, H. Briemberg, S. Jagannath, P. Wen, B. Barlogie, James Berenson, S. Singhal, D. Siegel, D. Irwin, M. Schuster and 10 more. Journal of Clinical Oncology, 2006
642 citations recorded by the source corpus.
Subfields: Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/a276830e4007f1f458ab5cb3448a52bafd24a262
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Chemotherapy‐induced neuropathy (2008, background): “…et al., 1990; Hovestadt et al., 1992; van Gerven et al., 1994; Cascinu et al., 1995; 2002; Gandara et al., 1995; Bogliun et al., 1996; Kemp et al., 1996; Rose, 1996; Roberts et al., 1997; Smyth et al., 1997; Planting et al., 1999; Schmidinger et al., 2000; Lorusso et al., 2003; Pace et al., 2003).”
- TRIM proteins and cancer (2011, background): “Although bortezomib is a useful therapy, there are often side effects associated with its use, such as neuropath”
- Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. (2007, neutral): “painful peripheral neuropathy (16) and thrombocytopenia (17)”
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006, result): “However, an examination of peripheral neuropathy in two MM studies found no correlation between overall incidence and baseline neuropathy or type of prior therapy, though severe neuropathy was more frequent in the presence of baseline neuropathy.(53) Hematologic AEs were less frequent in this study ”
- Chemotherapy‐induced peripheral neurotoxicity: A critical analysis (2013, background): “0 mg/m(2) (Table 3).(69) Importantly, dose modification seemed to have”
- The role of ubiquitination in tumorigenesis and targeted drug discovery (2020, background): “Despite its promising results, some off-target and adverse effects, such as fatigue, asthenia, thrombocytopenia, peripheral neuropathy and gastrointestinal symptoms, also limit its application.(347,348) The off-target effects may lead to dose-limiting toxicity and subsequently result in permanent ne”
- Chemotherapy-Induced Peripheral Neuropathy: A Current Review (2017, background): “It is a reversible distal axonopathy.(58) Recently, it was discovered that subcutaneous delivery decreases the likelihood and severity of the neuropathy.”